P429Ivabradine as a prevention treatment of inappropriate sinus node tachycardia recurrence

Grigoryan, Svetlana; Hzarapetyan, L G

doi:10.1093/europace/euy015.240

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to metoprolol alone, the combination of ivabradine and metoprolol was more effective at lowering HR 21 . In two studies comparing ivabradine to β‐blockers, ivabradine produced comparable HR lowering, whereas a third study reported “more pronounced” HR reduction with ivabradine 22,27,28 …”

Section: Resultsmentioning

confidence: 98%

“…One study reported qualitative improvement in functional class, whereas another study did not observe a significant improvement in exercise tolerance 18,19 . Symptomatic control of IST or quality of life were reported in 11 studies, all reporting improvement with ivabradine 13,15,17–24,27 . In two separate studies, complete resolution of symptoms at end of the study were reported in 100% and 74% of patients, respectively 15,24 .…”

Section: Resultsmentioning

confidence: 99%

“…In two separate studies, complete resolution of symptoms at end of the study were reported in 100% and 74% of patients, respectively 15,24 . Ivabradine was associated with greater symptom resolution than placebo and fewer symptomatic events compared to β‐blockers 13,22,27 …”

Section: Resultsmentioning

confidence: 99%

“… 13–28 The majority of these studies (13) were observational cohort studies 14–21,23–26,28 . Only five studies utilized a control or comparator group 13,21,22,27,28 . Although all studies included patients with IST, typically refractory to standard therapy, two studies investigated IST in patients following heart transplant and another following atrioventricular nodal reentrant tachycardia ablation 18,23,28 .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

2020

View full text Add to dashboard Cite

Ivabradine lowers heart rate by inhibiting the hyperpolarization-activated current in pacemaker cells, and its use for the treatment of heart failure (HF) and ischemic heart disease (IHD) is well described. Ivabradine may be an attractive treatment option for other conditions for which a reduction in heart rate is desirable but less is known about its role in these settings. The primary objective was to perform a scoping review summarizing the literature evaluating novel uses for ivabradine other than HF and IHD in adults. PubMed and EMBASE were searched for articles for all dates through September 2019. Search strategies combined terms generic, commercial/trade, and international names for ivabradine. Manual search of references was also performed to identify additional articles. Studies were included if they were published in English, evaluated the efficacy of ivabradine for indications other than HF or IHD in patients aged 18 years or older, and the primary outcome included clinically relevant end points. Articles were screened first by title and abstract followed by full-text screening of the remaining articles. After removal of duplicates, 1807 records were screened for inclusion and 84 studies were included in this scoping review. Novel uses of ivabradine were reported for various tachyarrhythmias, valvular heart disease, premedication for coronary computed tomography angiography, perioperative risk reduction, sepsis with and without multi-organ dysfunction syndrome, cor pulmonale, reactive airway disease, and erectile dysfunction. This scoping review identified several potential novel uses for ivabradine in adults. This review may help to identify existing gaps where further research is needed to elucidate the role of ivabradine for indications beyond HF and IHD. KEY WORDS ivabradine, tachycardia, asthma, CT angiography, perioperative risk reduction, pulmonary hypertension, multi-organ dysfunction syndrome, valvular heart disease.

show abstract

Section: Resultsmentioning

confidence: 98%